Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile-Reference-Cited by-同舟云学术

Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile

Published:2016-06 Issue:6 Volume:10 Page:613-619
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Wang Bin¹,Chen Liang¹,Chang Hao-Teng²³

Affiliation:

1. Department of Hepatobiliary Surgery, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang 322100, China

2. Graduate Institute of Basic Medical Science, College of Medicine, China Medical University, Taichung 40402, Taiwan

3. Department of Computer Science & Information Engineering, Asia University, Taichung 41354, Taiwan

Abstract

Cholangiocarcinoma (CCA) is a devastating malignancy that is difficult to treat because of its insensitivity to conventional therapies and the inability to detect early tumor formation. Novel molecular techniques have enabled the use of serum and bile markers for CCA diagnosis and prognosis. Herein, we summarize the principal characteristics of serum and bile markers of CCA. Biomarkers such as interleukin-6, matrix metalloproteinases, serotonin (5-hydroxytryptamine) and bile acids have shown promise for improving CCA diagnosis. Several markers such as CYFRA 21-1, MK-1 and C-reactive protein were recently shown to be effective for CCA prognosis.

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2015-0062

Reference62 articles.

1. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

2. The Epidemiology of Cholangiocarcinoma

3. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma

4. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis

5. The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BCLAF1 is Expressed as a Potential Anti-oncogene in Bile Duct Cancer;Biochemical Genetics;2024-01-10

2. BCLAF1 is expressed as an oncogene in Bile Duct Cancer;2023-08-23

3. Identification of a immune-related gene signature as a novel prognostic biomarker of cholangiocarcinoma;2023-08-17

4. Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update;Intractable & Rare Diseases Research;2022-11-30

5. Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models;Cancer & Metabolism;2021-03-16